0.839
0.01%
-0.000100
Pre-market:
.8499
0.0109
+1.30%
Ginkgo Bioworks Holdings Inc stock is currently priced at $0.839, with a 24-hour trading volume of 32.16M.
It has seen a -0.01% decreased in the last 24 hours and a -8.16% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8502 pivot point. If it approaches the $0.7689 support level, significant changes may occur.
Previous Close:
$0.8391
Open:
$0.8225
24h Volume:
32.16M
Market Cap:
$1.86B
Revenue:
$251.46M
Net Income/Loss:
$-892.87M
P/E Ratio:
-1.1817
EPS:
-0.71
Net Cash Flow:
$-336.30M
1W Performance:
-8.80%
1M Performance:
-8.16%
6M Performance:
-42.53%
1Y Performance:
-32.88%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
877 422 5362
Address
27 Drydock Avenue, 8th Floor, Boston
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Nov-29-22 | Initiated | Berenberg | Buy |
Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-02-22 | Resumed | Cowen | Outperform |
Feb-23-22 | Initiated | Goldman | Neutral |
Feb-01-22 | Initiated | BofA Securities | Neutral |
Jan-28-22 | Initiated | BofA Securities | Buy |
Jan-07-22 | Initiated | BTIG Research | Buy |
Nov-29-21 | Initiated | Jefferies | Buy |
Oct-13-21 | Initiated | Raymond James | Outperform |
Oct-12-21 | Initiated | William Blair | Outperform |
Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
4 Small-Cap Value Stocks That Could Go Parabolic
The Motley Fool
Harry Sloan Acquires 297619 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stock - Defense World
Defense World
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Update - MarketBeat
MarketBeat
Ginkgo Bioworks (NYSE:DNA) Stock Price Down 7.9% on Analyst Downgrade - Defense World
Defense World
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Growth in Short Interest - Defense World
Defense World
Ginkgo slips as BTIG cuts to Sell on strategic shift - MSN
MSN
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Ginkgo Bioworks Holdings Inc (DNA) Revenue 2024
DNA reported a revenue (TTM) of $251.46 million for the quarter ending December 31, 2023, a -47.36% decline year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Net Income 2024
DNA net income (TTM) was -$892.87 million for the quarter ending December 31, 2023, a +57.58% increase year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Cash Flow 2024
DNA recorded a free cash flow (TTM) of -$336.30 million for the quarter ending December 31, 2023, a -10.45% decrease year-over-year.
Ginkgo Bioworks Holdings Inc (DNA) Earnings per Share 2024
DNA earnings per share (TTM) was -$0.47 for the quarter ending December 31, 2023, a +63.57% growth year-over-year.
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to advance treatments for orphan and rare diseases. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Cap:
|
Volume (24h):